PRR:
- cvac already in phase II/III clinical trial, hopefully a couple of years away from fda approval (fingers crossed).
- based on a technology already approved, with improvements in methodology, hopefully increasing efficacy
- designed for muc-1 cancers, namely ovarian, hopefully others in the future
NRT:
- new laboratory based drug, recently patented
- yet to start human trials, as kbear stated, a decade away from approval
- would most likely target brain cancer
prr vs nrt product differences, page-3
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.005(1.49%) |
Mkt cap ! $493.8M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 34.0¢ | 33.0¢ | $1.233M | 3.670M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 484808 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 52319 | 5 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |